- Home
- LEGN
as 04-18-2025 1:39pm EST
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.0B | IPO Year: | 2020 |
| Target Price: | $79.00 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.27 - $60.87 | Next Earning Date: | 05-12-2025 |
| Revenue: | $627,241,000 | Revenue Growth: | 119.97% |
| Revenue Growth (this year): | 66.92% | Revenue Growth (next year): | 51.77% |
Latest Legend Biotech Corporation News
LEGN Breaking Stock News: Dive into LEGN Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Exploring US High Growth Tech Stocks
Zacks
3 days ago
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?
MT Newswires
4 days ago
Legend Biotech Says Carvykti Sales Reach $369 Million
Zacks
10 days ago
Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains?
TipRanks
18 days ago
Biotech stocks slide as Marks resignation seen being negative for sector
Simply Wall St.
a month ago
Legend Biotech Full Year 2024 Earnings: Beats Expectations
GuruFocus.com
a month ago
Legend Biotech Corp (LEGN) Q4 2024 Earnings Call Highlights: Record CARVYKTI Sales and ...
Thomson Reuters StreetEvents
a month ago
Q4 2024 Legend Biotech Corp Earnings Call
Compare LEGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LEGN Legend Biotech Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.